/Resmed%20Inc_%20HQ%20photo-by%20JHVEPhoto%20via%20iStock.jpg)
San Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. Valued at $32.1 billion, the company is expected to release its Q3 2026 earnings soon.
Ahead of the event, analysts expect the company’s EPS to be $2.77 on a diluted basis, up 16.9% from $2.37 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.